




Christian Wagner (Autor)  
**Predicting the Oral Absorption of Poorly Soluble  
Drugs**



<https://cuvillier.de/de/shop/publications/6557>

Copyright:  
Cuvillier Verlag, Inhaberin Annette Jentsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen,  
Germany  
Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>



## Acknowledgements

## Table of Contents

## List of Abbreviations

<b>1.</b>	<b>Introduction</b>	<b>1</b>
<b>1.1.</b>	<b>Classification of Poorly Soluble Drugs</b>	<b>2</b>
<b>1.1.1.</b>	<b><i>The Biopharmaceutics Classification Scheme (BCS)</i></b>	<b>2</b>
<b>1.1.2.</b>	<b><i>The Biopharmaceutics Drug Disposition Classification Scheme (BDDCS)</i></b>	<b>3</b>
<b>1.2.</b>	<b>Intraluminal Events in the Context of Oral Absorption and Factors that Limit the Bioavailability of Orally Administered Drugs</b>	<b>4</b>
<b>1.2.1.</b>	<b><i>Solubility, Dissolution, and Precipitation</i></b>	<b>6</b>
<b>1.2.2.</b>	<b><i>Complexation, Degradation</i></b>	<b>9</b>
<b>1.2.3.</b>	<b><i>Permeability Considerations</i></b>	<b>9</b>
<b>1.2.4.</b>	<b><i>Site-Specific Absorption</i></b>	<b>10</b>
<b>1.2.5.</b>	<b><i>Exotransport</i></b>	<b>10</b>
<b>1.2.6.</b>	<b><i>First Pass Metabolism</i></b>	<b>10</b>
<b>1.3.</b>	<b>Current Methods for Predicting the Permeability of Drugs</b>	<b>11</b>
<b>1.3.1.</b>	<b><i>Jejunal Perfusion Experiments</i></b>	<b>11</b>
<b>1.3.2.</b>	<b><i>In Vitro Techniques for Predicting the Intestinal Permeability of a Drug</i></b>	<b>12</b>
<b>1.3.2.1.</b>	<b><i>Parallel Artificial Membrane Permeability Assay (PAMPA)</i></b>	<b>12</b>
<b>1.3.2.2.</b>	<b><i>Surface Activity Profiling (SAP)</i></b>	<b>12</b>
<b>1.3.2.3.</b>	<b><i>Estimation Using Physicochemical Drug Properties</i></b>	<b>13</b>
<b>1.3.2.4.</b>	<b><i>Caco 2 Cell Assay</i></b>	<b>13</b>
<b>1.3.2.5.</b>	<b><i>HT-29 Cell Assay</i></b>	<b>14</b>
<b>1.3.2.6.</b>	<b><i>MDCK II Cell Assay</i></b>	<b>14</b>
<b>1.3.2.7.</b>	<b><i>LLC-PK1 Cell Assay</i></b>	<b>14</b>



<b>1.4.</b>	<b>Current Methods for Predicting the Release Characteristics of Drug Products</b>	<b>15</b>
<b>1.4.1.</b>	<b><i>Compendial Dissolution Methods</i></b>	<b>15</b>
1.4.1.1.	<i>Compendial Dissolution Media</i>	15
1.4.1.2.	<i>Compendial Dissolution Apparatus</i>	16
<b>1.4.2.</b>	<b><i>Biorelevant Dissolution Testing</i></b>	<b>17</b>
<b>1.5.</b>	<b>Mathematical Description of Dissolution and Release</b>	<b>22</b>
<b>1.5.1.</b>	<b><i>Fick's Diffusion Law and Noyes-Whitney Kinetics</i></b>	<b>22</b>
<b>1.5.2.</b>	<b><i>Zero Order Dissolution Kinetics</i></b>	<b>23</b>
<b>1.5.3.</b>	<b><i>First Order Dissolution Kinetics</i></b>	<b>24</b>
<b>1.5.4.</b>	<b><i>Weibull Distribution</i></b>	<b>25</b>
<b>1.5.5.</b>	<b><i>Higuchi Model</i></b>	<b>26</b>
<b>1.5.6.</b>	<b><i>Korsmeyer-Peppas Kinetics</i></b>	<b>27</b>
<b>1.5.7.</b>	<b><i>Dissolution Kinetics in Swellable, Erodible Matrices</i></b>	<b>28</b>
<b>1.6.</b>	<b>Effect of Food on Drug Absorption</b>	<b>28</b>
<b>1.6.1.</b>	<b><i>Physiological Changes in Response to Meal Ingestion</i></b>	<b>28</b>
<b>1.6.2.</b>	<b><i>Possible Effects of Food on the Performance of a Drug or Drug Formulation</i></b>	<b>30</b>
1.6.2.1.	<i>Gastric Conditions</i>	30
1.6.2.2.	<i>Small Intestinal Conditions</i>	31
1.6.2.3.	<i>Further Considerations for Food Effects</i>	31
<b>1.6.3.</b>	<b><i>Prediction of Food Effects</i></b>	<b>32</b>
1.6.3.1.	<i>BCS-Based Predictions</i>	32
1.6.3.2.	<i>Dissolution Studies</i>	33
1.6.3.3.	<i>Preclinical Studies</i>	33
1.6.3.4.	<i>Combining Laboratory and Pharmacokinetic Data</i>	33
<b>1.7.</b>	<b>Physiologically Based Pharmacokinetic (PBPK) Modeling</b>	<b>33</b>
<b>1.8.</b>	<b>Aim of the Thesis and Issues Addressed in this Work</b>	<b>40</b>



<b>2.</b>	<b>Results and Discussion</b>	<b>41</b>
<b>2.1.</b>	<b>Combining Dissolution Testing and PBPK Modeling for Establishing <i>in Vitro</i> – <i>in Silico</i> – <i>in Vivo</i> Correlations (IVISIVC) – Advantages and Limitations</b>	<b>41</b>
<b>2.1.1.</b>	<b><i>Establishing IVISIVC – Neutral Drugs</i></b>	<b>44</b>
<b>2.1.2.</b>	<b><i>Establishing IVISIVC – Weakly Acidic Drugs</i></b>	<b>46</b>
<b>2.1.3.</b>	<b><i>Establishing IVISIVC – Weakly Basic Drugs</i></b>	<b>56</b>
<b>2.1.3.1.</b>	<b><i>Theoretical Models for Simulating Drug Precipitation</i></b>	<b>57</b>
<b>2.1.3.2.</b>	<b><i>In Vitro Models for Simulating Drug Precipitation</i></b>	<b>58</b>
<b>2.1.4.</b>	<b><i>What is the Benefit of Coupling Dissolution Results with PBPK Models? A Statement of How to Establish IVISIVC</i></b>	<b>63</b>
<b>2.2.</b>	<b>PBPK Models to Predict the Pharmacokinetics of Poorly Soluble Drugs – A Guide to Appropriate Model Selection</b>	<b>68</b>
<b>2.2.1.</b>	<b><i>From 2001 to Now – The Evolution of the STELLA® PBPK Model</i></b>	<b>68</b>
<b>2.2.2.</b>	<b><i>A Comparison of the STELLA®-Based Model with Commercial PBPK Models: Advantages and Limitations</i></b>	<b>74</b>
<b>2.2.3.</b>	<b><i>Which PBPK Model Covers My Situation Best?</i></b>	<b>79</b>
<b>2.2.4.</b>	<b><i>Regulatory Applications of PBPK Modeling</i></b>	<b>82</b>
<b>3.</b>	<b>Summary and Outlook</b>	<b>86</b>
<b>4.</b>	<b>German Summary (Deutsche Zusammenfassung)</b>	<b>89</b>
<b>5.</b>	<b>References</b>	<b>94</b>
<b>6.</b>	<b>Publications</b>	<b>118</b>
<b>6.1.</b>	<b>Publication List</b>	<b>118</b>
<b>6.1.1.</b>	<b><i>Peer-Reviewed Papers</i></b>	<b>118</b>
<b>6.1.2.</b>	<b><i>Review Articles</i></b>	<b>118</b>
<b>6.1.3.</b>	<b><i>Book Chapter</i></b>	<b>118</b>
<b>6.1.4.</b>	<b><i>Poster Presentations</i></b>	<b>119</b>



6.2.	<b>Personal Contributions to Peer-Reviewed Papers and Book Chapter</b>	<b>121</b>
6.3.	<b>Original Publications (Peer-Reviewed Papers and Book Chapter)</b>	<b>122</b>
6.3.1.	<i>Biorelevant in Vitro Dissolution Testing of Products Containing Micronized or Nanosized Fenofibrate with a View to Predicting Plasma Profiles</i>	<b>122</b>
6.3.2.	<i>Predicting the Oral Absorption of a Poorly Soluble, Poorly Permeable Weak Base using Biorelevant Dissolution and Transfer Model Tests Coupled with a Physiologically Based Pharmacokinetic Model</i>	<b>130</b>
6.3.3.	<i>Utilizing in Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation</i>	<b>142</b>
6.3.4.	<i>In Vitro – in Silico Tools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds. Chapter 12 in: Predictive ADMET: Integrated Approaches in Drug Discovery and Development</i>	<b>157</b>
7.	<b>Curriculum Vitae</b>	<b>195</b>
8.	<b>Academic Teachers</b>	<b>201</b>